专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010130900A3 TRIAMINOPYRIMIDINE DERIVATIVES AS CDC25 PHOSPHATASE INHIBITORS 审中-公开
标题翻译：作为CDC25磷酸酶抑制剂的三亚氨基嘧啶衍生物
公开(公告)号：WO2010130900A3
公开(公告)日：2011-04-07
申请号：PCT/FR2010000371
申请日：2010-05-12
申请人： IPSEN PHARMA SAS , LIBERATORE ANNE-MARIE , PREVOST GREGOIRE , AUVIN SERGE , BREHU LAETITIA
发明人： LIBERATORE ANNE-MARIE , PREVOST GREGOIRE , AUVIN SERGE , BREHU LAETITIA
IPC分类号： C07D239/50 , A61K31/506 , A61P35/00 , C07D401/14 , C07D403/12
CPC分类号： C07D239/50 , C07D401/14 , C07D403/12
摘要： The invention relates to novel triaminopyrimidine derivatives of formula (I) wherein Rl, R2, L, R3, R4a, R5a, R4b, R5b are variables. Said products have a Cdc25 phosphatase inhibiting activity. The invention also relates to a method for the synthesis of said compounds, to therapeutic compositions containing said products, and to the use thereof as medicaments.
摘要翻译：本发明涉及式（I）的新的三氨基嘧啶衍生物，其中R1，R2，L，R3，R4a，R5a，R4b，R5b是可变的。所述产品具有Cdc25磷酸酶抑制活性。本发明还涉及用于合成所述化合物的方法，含有所述产品的治疗组合物及其作为药物的用途。

2. 发明申请

WO2006067312A3 PAINKILLING ASSOCIATION COMPRISING A DIHYDROIMIDAZOPYRAZINE DERIVATIVE 审中-公开
标题翻译：包含二氢咪唑并吡啶衍生物的结合协会
公开(公告)号：WO2006067312A3
公开(公告)日：2007-05-31
申请号：PCT/FR2005003162
申请日：2005-12-16
申请人： SOD CONSEILS RECH APPLIC , AUGUET MICHEL , FAVRE CHRISTINE , PREVOST GREGOIRE , CHABRIER DE LASSAUNIERE PIERRE
发明人： AUGUET MICHEL , FAVRE CHRISTINE , PREVOST GREGOIRE , CHABRIER DE LASSAUNIERE PIERRE
IPC分类号： A61K45/06 , A61K31/4985 , A61P29/00
CPC分类号： A61K45/06 , A61K31/4985 , A61K2300/00
摘要： The invention relates to a product comprising (1R)-1-[({(2R)-2-amino-3-[(8S)-8-(cycloliexylmethyl)-2-phenyl-5,6-dihydroimidazo [1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine in association with an analgesic agent selected form morphine, the similar or a morphine derivative, sodium channel inhibitors, non-steroidal antiflammatory agents (AINS), glutamatergic system inhibitors, tricycle antidepressants and gabaergic derivatives for simultaneous therapeutic use which is separated or spread out over the time for pain treatment or prevention.
摘要翻译：本发明涉及包含（1R）-1 - [（{（2R）-2-氨基-3 - [（8S）-8-（环丙基甲基）-2-苯基-5,6-二氢咪唑并[1,2 -a]吡嗪-7（8H） - 基] -3-氧代丙基}二硫代）甲基] -2 - [（8S）-8-（环己基甲基）-2-苯基-5,6-二氢咪唑并[1,2- ]吡嗪-7（8H） - 基] -2-氧代乙胺与选自吗啡的止痛剂相关联，吗啡衍生物，钠通道抑制剂，非甾体抗炎剂（AINS），谷氨酸能系统抑制剂，三轮车抗抑郁药和用于同时治疗的gabaergic衍生物，其用于疼痛治疗或预防的时间分离或分布。

3. 发明申请

WO2006067310A3 USE OF A DIHYDROIM1DAZOPYRAZINE DERIVATIVE FOR TREATING OR PREVENTING PAIN 审中-公开
标题翻译：用于治疗或预防疼痛的DIHYDROIM1DAZOPYRAZINE DERIVATIVE的用途
公开(公告)号：WO2006067310A3
公开(公告)日：2007-05-10
申请号：PCT/FR2005003160
申请日：2005-12-16
申请人： SOD CONSEILS RECH APPLIC , AUGUET MICHEL , FAVRE CHRISTINE , PREVOST GREGOIRE , CHABRIER DE LASSAUNIERE PIERRE
发明人： AUGUET MICHEL , FAVRE CHRISTINE , PREVOST GREGOIRE , CHABRIER DE LASSAUNIERE PIERRE
IPC分类号： A61K45/06 , A61K31/4985 , A61P29/00
CPC分类号： A61K45/06 , A61K31/4985 , A61K2300/00
摘要： The invention relates to the use of (1 R)-1-[({(2R)-2-amino-3-[(8S)-8- (cyclohexylmethyl)-2-phényl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-yl]-3- oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2- a]pyrazine-7(8H)-yl]-2-oxoethylamine or an pharmaceutically acceptable salt thereof for preparing a drug for preventing or treating pain.
摘要翻译：本发明涉及（1R）-1 - [（{（2R）-2-氨基-3 - [（8S）-8-（环己基甲基）-2-苯基-5,6-二氢咪唑并[ （8H） - 基] -3-氧代丙基}二硫基）甲基] -2 - [（8S）-8-（环己基甲基）-2-苯基-5,6-二氢咪唑并[1,2- a]吡嗪-7（8H） - 基] -2-氧代乙胺或其药学上可接受的盐在制备用于预防或治疗疼痛的药物中的用途。

4. 发明申请

WO2004028541A2 COMPOSITION FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA AND METHOD OF USE THEREOF 审中-公开
标题翻译：治疗鼻咽癌的组合物及其使用方法
公开(公告)号：WO2004028541A2
公开(公告)日：2004-04-08
申请号：PCT/IB2003/004922
申请日：2003-09-29
申请人： SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. , CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE , PREVOST, Gregoire , BUSSON, Pierre , VICAT, Jean-Michel
发明人： PREVOST, Gregoire , BUSSON, Pierre , VICAT, Jean-Michel
IPC分类号： A61K31/4985
CPC分类号： A61K31/4985 , A61K31/5517 , A61K2300/00
摘要： Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracyline.
摘要翻译：公开了一种可用于治疗鼻咽癌的新型药物组合，所述新型药物组合包含法呢基转移酶抑制剂和一种或多种蒽环类药物中的一种或多种。

5. 发明申请

WO0139720A3 DNA POLYMERASE INHIBITORS, MIKANOLIDE AND DIHYDROMIKANOLIDE 审中-公开
标题翻译： DNA聚合酶抑制剂，甘露醇和二氢异氰脲酸酯
公开(公告)号：WO0139720A3
公开(公告)日：2002-04-04
申请号：PCT/FR0003337
申请日：2000-11-30
申请人： SOD CONSEILS RECH APPLIC , TENG BENG POON , PREVOST GREGOIRE , BREZAK PANNETIER MARIE CHRISTI , MOUMEN MOHAMED
发明人： TENG BENG POON , PREVOST GREGOIRE , BREZAK PANNETIER MARIE-CHRISTI , MOUMEN MOHAMED
IPC分类号： C12N9/99 , A61K20060101 , A61K6/00 , A61K31/343 , A61K31/365 , A61K36/00 , A61K36/185 , A61K36/28 , A61K127/00 , A61P31/12 , A61P33/00 , A61P33/02 , A61P33/06 , A61P35/00 , B01D11/02 , C07D493/22 , A61K35/78
CPC分类号： A61K36/28
摘要： The invention concerns DNA polymerase inhibitors, namely mikanolide and dihydromikanolide and dihydromikanolide-enriched extracts. Said compounds or mixtures can be used for preparing medicines designed to treat proliferative diseases, in particular cancer, viral diseases or parasitic diseases provoked by protozoae (for example malaria ) or protists (for example, diseases caused by amoebae).
摘要翻译：本发明涉及DNA聚合酶抑制剂，即咪喹啉和二氢新鲜内酯和富含二氢海康酸的提取物。所述化合物或混合物可用于制备设计用于治疗增殖性疾病，特别是由原生动物（例如疟疾）或原生生物（例如由变形虫引起的疾病）引起的癌症，病毒性疾病或寄生虫病的药物。

6. 发明申请

WO0144467A3 METHOD FOR OBTAINING HUMAN CDC25 PHOSPHATASES AND METHOD FOR IDENTIFYING HUMAN CDC25 PHOSPHATASE MODULATORS 审中-公开
标题翻译：用于获得人CDC25磷酸化的方法和识别人CDC25磷酸酯酶调节剂的方法
公开(公告)号：WO0144467A3
公开(公告)日：2001-12-27
申请号：PCT/FR0003496
申请日：2000-12-13
申请人： SOD CONSEILS RECH APPLIC , GOUBIN GRAMATICA FRANCOISE , DUCOMMUN BERNARD , PREVOST GREGOIRE
发明人： GOUBIN-GRAMATICA FRANCOISE , DUCOMMUN BERNARD , PREVOST GREGOIRE
IPC分类号： G01N33/53 , C07K19/00 , C12N1/21 , C12N9/16 , C12N15/09 , C12N15/12 , C12P21/00 , C12Q1/42 , G01N33/15 , G01N33/566 , C12N15/55 , C07K14/47 , C12N15/62
CPC分类号： C12N9/16 , C07K2319/00
摘要： The invention concerns a method for obtaining human cdc 25B1, cdc25B2, cdcB3 and cdc25C phosphatases. More particularly, the invention concerns a protein for fusion between human cdc25B1, cdc25B2, cdcB3 or cdc25C phosphatase and the maltose binding protein (MBP) of Escherichia coli , the DNA sequence coding for said fusion protein, a method for preparing said fusion protein and a method for identifying human cdc25B1, cdc25B2, cdcB3 or cdc25C protein modulators.
摘要翻译：本发明涉及一种获得人类cdc 25B1，cdc25B2，cdcB3和cdc25C磷酸酶的方法。更具体地，本发明涉及用于在人cdc25B1，cdc25B2，cdcB3或cdc25C磷酸酶之间融合的蛋白质和大肠杆菌的麦芽糖结合蛋白（MBP），编码所述融合蛋白的DNA序列，用于制备所述融合蛋白和用于鉴定人cdc25B1，cdc25B2，cdcB3或cdc25C蛋白质调节剂的方法。

7. 发明申请

WO0209686A3 CDC25 PHOSPHATASE INHIBITORS 审中-公开
标题翻译： CDC25磷酸酶抑制剂
公开(公告)号：WO0209686A3
公开(公告)日：2003-10-09
申请号：PCT/FR0102443
申请日：2001-07-26
申请人： SOD CONSEILS RECH APPLIC , PREVOST GREGOIRE , BREZAK PANNETIER MARIE-CHRISTI , GALCERA CONTOUR MARIE-ODILE , THURIEAU CHRISTOPHE , GOUBIN-GRAMATICA FRANCOISE , DUCOMMUN BERNARD , LANCO CHRISTOPHE
发明人： PREVOST GREGOIRE , BREZAK PANNETIER MARIE-CHRISTI , GALCERA CONTOUR MARIE-ODILE , THURIEAU CHRISTOPHE , GOUBIN-GRAMATICA FRANCOISE , DUCOMMUN BERNARD , LANCO CHRISTOPHE
IPC分类号： C07D295/12 , A61K31/04 , A61K31/137 , A61K31/166 , A61K31/18 , A61K31/222 , A61K31/24 , A61K31/381 , A61K31/4164 , A61K31/445 , A61K31/495 , A61K31/63 , A61K31/661 , A61K31/6615 , A61P17/14 , A61P21/00 , A61P25/00 , A61P25/28 , A61P31/12 , A61P33/00 , A61P35/00 , A61P43/00 , C07C69/157 , C07C211/53 , C07C215/78 , C07C215/80 , C07C217/84 , C07C229/36 , C07C235/66 , C07C303/38 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/37 , C07D211/96 , C07D233/84 , C07D241/04 , C07D295/135 , C07D295/155 , C07D295/192 , C07D295/26 , C07D333/22 , C07D333/34 , C07D333/38 , C07F9/12
CPC分类号： C07D295/26 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/381 , A61K31/445 , A61K31/495 , A61K31/63 , C07C217/84 , C07C229/36 , C07C235/66 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/37 , C07D233/84 , C07D295/135 , C07D295/192 , C07D333/22 , C07D333/34 , C07F9/12
摘要： The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR R radical wherein R and R represent a hydrogen atom or an alkyl radical or R and R form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR R -, -O-, -S and NR - radicals, R and R representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R5 representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or more radicals selected independently among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR R radical wherein R and R represent a hydrogen atom or an alkyl radical; B represents a -(CH2)i-(CO)- or -NH-CO-(CH2)n or -(CH2)p and i and n being integers from 0 to 2 and p being an integer from 0 to 1; W represents a hydrogen atom or an alkyl radical; X represents a -(CH2)q- or (CH2)j-CO-(CH2)r-, q being an integer from 1 to 4 and j and r being integers from 0 to 6; Y represents in particular a nitrophenyl, aminophenyl, alkylaminophenyl or dialkylaminophenyl radical or the radical (T).
摘要翻译：本发明涉及新的cdc25磷酸酶抑制剂，特别是对应于通式（I）的cdc25-C，其中：A代表一个或多个独立地选自卤原子和烷基，羟基，烷氧基，烷硫基或NR 1 R 2基团，其中R 1和R 2表示氢原子或烷基或R 1和R 2与氮原子，含有1至2个杂原子的4至7个成员的杂环，完成杂环所需的成员独立地选自CR 3 - ， - O - ， - S和NR 5 - 基团 R 3和R 4每次涉及氢原子或烷基，羟基，烷氧基，氨基，烷基氨基或二烷基氨基时独立地表示，并且R 5独立地表示每次涉及氢原子或烷基或者A表示被任选取代的苯基取代的苯基在卤素原子和烷基，羟基，烷氧基，烷硫基或NR 1 R 2基团中独立选择的一个或多个基团，其中R 1和R 2表示氢原子或烷基; B表示 - （CH2）i-（CO） - 或-NH-CO-（CH2）n或 - （CH2）p，i和n为0至2的整数，p为0至1的整数; W表示氢原子或烷基; X表示 - （CH 2）q - 或（CH 2）j -CO-（CH 2）r - ，q为1至4的整数，j和r为0至6的整数; Y特别表示硝基苯基，氨基苯基，烷基氨基苯基或二烷基氨基苯基或基团（T）。

8. 发明申请

WO0002881A3 USE OF CYSTEINE DERIVATIVES FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM THE FORMATION OF HETEROTRIMERIC G PROTEIN 审中-公开
标题翻译：用于制备用于治疗由异源G蛋白形成形成的病理学的药物的CYSTEINE衍生物的使用
公开(公告)号：WO0002881A3
公开(公告)日：2000-03-16
申请号：PCT/FR9901609
申请日：1999-07-05
申请人： SOD CONSEILS RECH APPLIC , PREVOST GREGOIRE , LONCHAMPT MARIE ODILE , GORDON THOMAS
发明人： PREVOST GREGOIRE , LONCHAMPT MARIE-ODILE , GORDON THOMAS
IPC分类号： C07D233/64 , A61K31/198 , A61K31/223 , A61K31/4164 , A61K31/421 , A61K31/426 , A61K31/495 , A61K31/496 , A61K31/4985 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/00 , A61P9/12 , A61P15/00 , A61P25/02 , A61P25/28 , A61P31/12 , A61P35/00 , A61P37/02 , C07D241/04 , C07D263/32 , C07D277/28 , C07D417/06 , C07D487/04 , C12N9/88
CPC分类号： C07D487/04 , A61K31/223 , A61K31/498 , A61K31/4985 , C12N9/88
摘要： The invention concerns the use of cysteine derivatives for preparing a medicine for treating diseases resulting from the formation of heterotrimeric G protein. Said diseases include in particular diseases related to biological functions or the following disorders: smell, taste, light perception, neurotransmission, neurodegeneration, functioning of endocrine and exocrine glands, autocrine and paracrine regulation, blood pressure, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, benign and malign proliferative diseases. Said cystein derivatives comprise in particular: bis-1,1'-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazol[1,2a]pyrazine (I) disulphide; and bis-1,1'-7- (2-amino- 1-oxo-thiopropyl- (2-(1-naphthyl)-8- (2-methylpropyl)- 5,6,7,8- tetrahydroimidazol [1,2a]pyrazin-7-yl) disulphide (II).
摘要翻译：本发明涉及半胱氨酸衍生物用于制备用于治疗由异三聚体G蛋白形成引起的疾病的药物的用途。所述疾病特别包括与生物功能或以下疾病有关的疾病：气味，味觉，光感知，神经传递，神经变性，内分泌和外分泌腺的功能，自分泌和旁分泌调节，血压，胚胎发生，良性细胞增殖，肿瘤形成，病毒感染，免疫功能，糖尿病，肥胖，良性和恶性增殖性疾病。所述半胱氨酸衍生物特别包括：双-1,1' - [7-（2-氨基-1-氧代-3-硫丙基）-8-（环己基甲基）-2-（2-甲氧基苯基）-5,6,7 ，8-四氢咪唑并[1,2a]吡嗪（I）二硫化物; 和双-1,1'- -7-（2-氨基-1-氧代 - 硫丙基 - （2-（1-萘基）-8-（2-甲基丙基）-5,6,7,8-四氢咪唑并[ 2a]吡嗪-7-基）二硫化物（II）。

9. 发明申请

WO2005000852A3 PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT 审中-公开
标题翻译：含有至少一种磷酸酯酶的产品CDC25抑制剂与至少一种其他抗感染剂
公开(公告)号：WO2005000852A3
公开(公告)日：2005-06-30
申请号：PCT/FR2004001586
申请日：2004-06-24
申请人： SOD CONSEILS RECH APPLIC , PREVOST GREGOIRE , BREZAK PANNETIER MARIE-CHRISTI , DIOLEZ CHRISTIAN
发明人： PREVOST GREGOIRE , BREZAK PANNETIER MARIE-CHRISTINE , DIOLEZ CHRISTIAN
IPC分类号： A61K45/06 , A61P35/00 , C07D263/56 , C07D263/57 , C07D277/66 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D519/00 , A61K31/425 , A61K31/42 , C07D277/64
CPC分类号： A61K45/06 , C07D519/00
摘要： The invention relates to a product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent for simultaneous, separate or staggered therapeutic use during treatment for cancer. According to the invention, the other anticancer agent is preferably selected from: DNA base analogs such as 5-fluorouracil; inhibitors of type I and/or type II topoisomerases, such as camptothecin and the analogs thereof, doxorubicin or amsacrine; compounds interacting with the cellular spindle, for example, paclitaxel (Taxol); compounds acting on the cytoskeleton, such as vinblastine; inhibitors of the transduction of the signal passing via the heterotrimeric G proteins; prenyltransferase inhibitors, and especially farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; folic acid antagonists such as methotrexate; and inhibitors of DNA synthesis and cellular division, such as mitomycin C. The invention also relates to (1R)-1-[({(2R)-2-amino--3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]--3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl--5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or the pharmaceutically acceptable salts thereof, that can be used as anticancer agents.
摘要翻译：本发明涉及含有至少一种磷酸酶Cdc25抑制剂与至少一种其他抗癌剂组合的产品，用于癌症治疗期间的同时，分离或交错的治疗用途。根据本发明，其它抗癌剂优选选自：DNA碱基类似物，如5-氟尿嘧啶; I型和/或II型拓扑异构酶的抑制剂，如喜树碱及其类似物，多柔比星或amsacrine; 与细胞纺锤体相互作用的化合物，例如紫杉醇（紫杉醇）; 作用于细胞骨架的化合物，如长春花碱; 通过异源三聚体G蛋白的信号转导的抑制剂; 异戊烯转移酶抑制剂，特别是法呢基转移酶抑制剂; 细胞周期蛋白依赖性激酶（CDKs）抑制剂; 烷化剂如顺铂; 叶酸拮抗剂如甲氨蝶呤; 以及DNA合成和细胞分裂的抑制剂，例如丝裂霉素C.本发明还涉及（1R）-1 - [（{（2R）-2-氨基-3 - [（8S）-8-（环己基甲基） 2-苯基-5,6-二氢咪唑并[1,2-a]吡嗪-7（8H） - 基] - 3-氧代丙基}二硫代）甲基] -2 - [（8S）-8-（环己基甲基）-2 - 苯基-5,6-二氢咪唑并[1,2-a]吡嗪-7（8H） - 基] -2-氧代乙基胺或其药学上可接受的盐，可用作抗癌剂。

10. 发明申请

WO2006067311A3 CDC25 PHOSPHATASE INHIBITORS 审中-公开
标题翻译： CDC25磷酸酶抑制剂
公开(公告)号：WO2006067311A3
公开(公告)日：2006-08-17
申请号：PCT/FR2005003161
申请日：2005-12-16
申请人： SCIENT S C R A S SAS SOC DE CO , GALCERA CONTOUR MARIE-ODILE , BIGG DENNIS , PREVOST GREGOIRE , SIDHU ALBAN
发明人： GALCERA CONTOUR MARIE-ODILE , BIGG DENNIS , PREVOST GREGOIRE , SIDHU ALBAN
IPC分类号： C07D417/14 , A61K31/428 , A61P29/00 , A61P35/00 , A61P37/00 , C07D413/12 , C07D417/12
CPC分类号： C07D417/14 , C07D263/56 , C07D277/64
摘要： The invention relates to novel compounds comprising two or three benzothiazole-4,7-diones or benzooxazole-4,7-diones units which inhibit cdc25 phosphatases, in particular an cdc25-C phosphatase. Said compounds are usable, in particular for treating cancer.
摘要翻译：本发明涉及包含抑制cdc25磷酸酶，特别是cdc25-C磷酸酶的两个或三个苯并噻唑-4,7-二酮或苯并恶唑-4,7-二酮单元的新型化合物。所述化合物是可用的，特别是用于治疗癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式